Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SSSC-33
- Development stage
- Preclinical
- Modality
- Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
SSSC-33 is a novel Schiff base analogue of 2-aminobenzothiazole, identified for its potential in treating hepatocellular carcinoma. It has demonstrated significant antioxidant potential and the ability to reverse changes in cancerous liver in a diethylnitrosamine-induced rat model. In silico studies suggest favorable pharmacokinetic properties, including potential for oral activity, and molecular docking indicated interactions with checkpoint kinase 1 and vascular endothelial growth factor receptor 2.
- Other names
- SSSC-33-((benzo[d]thiazol-2-ylimino) methyl)phenol)
Beyond the preview
Go deeper on SSSC-33.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SSSC-33.